Tagged with Lithuania,

CEE Some of the biggest stories coming out of the Central and Eastern European (CEE) region’s pharma industry, including the European Bank’s EUR 25 million investment in Pelion Group; the amendments to Poland’s drug reimbursement act; Pfizer’s legal proceedings against Hungary, Poland and Romania, and Egis Pharma’s expansion beyond Hungary.  …

CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval in the US, Hungary’s windfall tax on pharma, Presage’s collaboration with Pure Biologics and Lithuania’s biotech ambitions.   Polpharma working…

Lithuania With the end of the Lithuanian Parliament’s Spring Session, a period of neverending discussions and misunderstandings has ended too, as the Parliament and the Ministry of Health have finally adopted a new medicines reimbursement system, writes Ruta Pumputienė.   Lithuanian Ministry of Health deserves compliments for getting involved in the…

Lithuania Ruta Pumputiene examines recent regulatory reform in Lithuania, as the Baltic nation attempts to introduce a holistic HTA mechanism for the evaluation of what to include on the country’s reimbursable medicines list.   It is not yet clear whether the new procedure will complicate and damage Lithuanian patients’ access to…

Baltics In terms of being able to access medicines, patients in the Baltic states fare poorly compared to many of their European counterparts. 135 new medicines were approved by regulators in Lithuania and Estonia in 2016, but only 38 and 30 were made available to patients respectively. Latvia fares even worse,…

Baltics As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they require for a new age of medical science. “There are a number of emerging trends underway that are forcing companies…

Lithuania Lukas Savickas, advisor to the prime minister of Lithuania, highlights the changes needed for the Lithuanian life science industry to become more competitive, while discussing the opportunities awaiting companies willing to invest in the country. Can you please introduce yourself to our international audience as well as the main points…

Lithuania Lithuania’s key economic indicators between 2015 and 2018: GDP growth, inflation, unemployment rate, and government budget. Lithuania’s pharma market in terms of both volume and value. Spending on public health in Lithuania. The Lithuanian pharma market split by dispensing types. The public funding of health and pharmaceuticals in Lithuania. Healthcare…

Lithuania The Top 20 pharma companies in Lithuania by value for 2017. J&J leads the way with a value of around EUR 35 million and market share of 6.3% bolstered by 63% year-on-year growth. Berin Chemie ranks second, while Novartis ranks third.

Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…

Lithuania Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders are, however, split on whether Lithuania truly holds the potential to become a biotech hub that can stand alongside nations…

Lithuania Aki Kasvi and Mindaugas Plieskis of Janssen Baltics discuss their strategic priorities, acting as a strategic partner within the region, and ensuring that patients can access their innovative latest-generation therapies Mr Kasvi, you were nominated to head up Janssen’s Lithuanian office back in November 2017. What was the strategic mission…